Posted inHematology-Oncology news Oncology
High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial
The FIGHT-203 phase 2 trial demonstrates that pemigatinib, a selective FGFR inhibitor, induces high rates of complete clinical and cytogenetic responses in patients with FGFR1-rearranged myeloid/lymphoid neoplasms, offering a potent targeted therapy for this aggressive hematologic malignancy.